Pacira BioSciences, Inc.
NASDAQPacira BioSciences enters the final stretch before its June 9 earnings with a notable split: the stock has bounced sharply while shorts have barely budged. The price action this week is the sharpest divergence in months. PCRX gained 9.2% over the past five sessions to close at $24.36, adding 4.3% on Tuesday alone. That recovery looks meaningful against a one-month backdrop that…
Snapshot as of 22 Jun 2026
Pacira BioSciences enters the final stretch before its June 9 earnings with a notable split: the stock has bounced sharply while shorts have barely budged. The price action this week is the sharpest divergence in…
PCRX heads into its May 1 earnings print with a notable divergence: short sellers are retreating while company insiders are cashing out. The short-side picture has shifted meaningfully heading into the release. Short…
Pacira BioSciences heads into its Q1 2026 earnings release — due after the close today — with two colliding stories: a meaningful short-covering wave over the past week, and an active proxy battle with a dissident…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PCRX — free to start on ORTEX.
Sign up for free →Open PCRX on ORTEX